Skip to content

A Clinical Study On Nar Farsi(Eczema)

A Randomized,Parallel Group,Open Label,Active Controlled Clinical Study To Evaluate The Safety And Efficacy Of A Topical Unani Formulation Compared With Clobetasol Propionate In The Management Of Nar Farsi(Eczema) - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098406
Enrollment
60
Registered
2025-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Topical Unani Formulation: Topical Unani formulation. .Form:Dimad(Paste)for topical application. .Quantity: Dimad(Paste)in sufficient quantity to be applied .Instructions: Dimad(Paste)

Sponsors

National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD), Hyderabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The following participants will be included in the study: 1)Participants of any sex aged between 18 to 60 years 2)Participants having the following symptoms: Erythema Scaling Excoriation Hyperpigmentation Burning sensation Itching

Exclusion criteria

Exclusion criteria: The following participants will be excluded: 1)Participants aged less than 18 years or more than 60 years 2)Participants on concomitant therapy. 3)Known case of Diabetes mellitus. 4)Pregnant or Lactating Women. 5)Significant Pulmonary,Cardiovascular,Hepato-renal Dysfunction. 6)Known cases of Immunocompromised states (HIV,AIDS, etc.),malignancies. 7)Participants not willing to attend treatment schedule regularly.

Design outcomes

Primary

MeasureTime frame
Change in EASI Score from baseline to 8 weeks of treatmentTimepoint: at baseline,2,4,6,8 week

Secondary

MeasureTime frame
1)Change in CDSQ score from baseline to 8 week. 2)systemic safety assessment.Timepoint: 1)at baseline,2,4,6,8, week. 2)at baseline and 8 week.

Countries

India

Contacts

Public ContactDR ANSARI HINA KAUSAR MOHAMMAD JALIL

National Research Institute Of Unani Medicine For Skin Disorder(NRIUMSD)

aarzu763@gmail.cm9032519286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026